FGF2 and neoplasm: Indeed, if on one hand bFGF was considered an unfavorable prognostic factor in GC [90,92], different evaluations advise only VEGF, not bFGF, as a reliable marker for assessing tumor progression and, in particular, clinicopathological factors or survival [93].